OncLive | Bringing the Global Oncology Community Together

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous... Read More >>

Cabozantinib Combinations Generate Excitement in RCC

SGO 2020: Niraparib/Bevacizumab Combo as Frontline Maintenance Shows Promise in Advanced Ovarian Cancer

At the Epicenter: How SCCA Braced Itself for COVID-19

FDA Grants Nivolumab/Ipilimumab Plus Chemo Priority Review in Frontline NSCLC

Paxalisib Shows Positive Survival Data in Glioblastoma

View More Stories >>

View Conference Coverage

2020 SGO Annual Meeting

2020 School of Gastrointestinal Oncology

2020 New York GU

2020 Miami Breast Cancer Conference

2020 HCC-TAG Conference

Dr. Mesa on Challenges in Myelofibrosis Treatment

Dr. Boisen on Scoring System for Optimal Debulking in Ovarian Cancer

Dr. Goy on the Progression of MCL Treatment

Dr. Awan on Future of Combo Regimens in CLL Treatment Paradigm

OncLive houses thousands of videos that provide updates and information.
See more Videos

Ep. 4: Currently Approved Therapies for Metastatic CSPC

Ep. 3: Addressing Cardiovascular Risk and Events in CSPC

Biosimilar Interchangeability in Practice

Evidence-Based Extrapolation for Biosimilars

Treatment Approach After IMpower150 Regimen

$Relapsed/Refractory HCC: Third-Line Approach$

The Complexity of Choosing Biosimilars in Oncology

OncLive houses thousands of videos that provide updates and information.
See more Videos

Importance of Risk Assessment in Renal Cell Carcinoma

Renal Cell Carcinoma: Early Management Strategies

Checkpoint Inhibitor Therapy in Prostate Cancer

PARP Inhibitors in Castrate-Resistant Prostate Cancer

Small-Cell Lung Cancer: Future Directions in Care

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

Recent Updates in HER2+ Breast Cancer

Updates in HER2-positive breast cancer that were presented at the 2019 San Antonio Breast Cancer Symposium.

View more >>>

Featured

Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW

Data and analysis shared at the 17th International Myeloma Workshop show that anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates have the potential to revolutionize the multiple myeloma treatment paradigm.

View more >>>